








It is my great honor to become Editorial Board Member of Universal Journal of Pharmaceutical 
Research (UJPR). It is also a great pleasure for me to be invited at speaking again for a period of 
time in addition to my previous publications. I do not know where to begin my written. The 
UJPR has grown up for two years. From aim and scope of UJPR, it has been covering a broad of 
multidisciplinary areas in pharmaceutical science including basic fields, molecular images, 
clinical trials and other medical practice, to increase the impact factor of journal. A considerable 
fact provide strong validation that authors might prepare high quality of their intensive original 
researches, the subject of pharmaceutical molecular mechanism of drugs, and the systemic 
exploration of medicinal herbs among folk medicines. 
In vitro and in vivo transgene experiments are continued ongoing. In clinical classical trials, the 
earliest palliative treatment of metastatic breast cancer by oophorectomy was initially reported 
by George Thomas Beatson in 1896, the father of anti-hormonal treatment of breast cancer. This 
implicate anti-hormonal tumorigenesis,which linked hormonally-driven cancers. Tumor cells 
share oncogenic receptor (Robinson R). It is previously reported that among these oncogenic 
receptor derivatives, oncogenic activating prolactin (PRL)/PRL receptor signaling linked to 
hyperprolactinemia and breast tumorigenesis; aberrant expression of lysophosphatidic acid 
receptor mediated the tumorigenicity of hepatocellular carcinoma (HCC) (Mazzocca A); and an 
additional member of vitamin K dependent Gas6 and protein S/Axl oncogenic receptor 
signalling (Burstyn-Cohen T;O'Bryan JP etal,1991; Hafizi S et al., 2006). Prolactin, 
phospholipid, growth hormone, vitamin A and protein S are natural substances in human body 
and important medicine. In recent advances, genetic deficiency of EpCAM was identified as the 
gene for congenital tufting enteropathy (Sivagnanam M; Kozan PA). An inherited defects in 
reduced cell membrane EGFR (the EGFR signaling ablation due to a loss-of-function mutation 
p.Gly428Asp) has been recorded in an infant with epithelial inflammation (Campbell P). I also 
consulted a tumoral girl with her abdominal much thinner and transparent epidermis, and with 
pustules. At present, pharmaceutical effects of monoclonal antibodies targeting directed 
oncogenic receptor immunotherapy (for examples oncogenic receptor EpCAM, oncogenic 
receptor EGFRv III, HER2 oncogenic receptor, oncogenic receptor derivative pml/RARa or also 
oncogenic pml/ RARa) moves initially patients trials to front center. Downregulating oncogenic 
receptors may be useful paradigm in currently the third line setting of clinical target therapy and 
in rendering our highlight on the understanding of cancer biology. It is at ' hot spot ' topics today. 
After browsing those publications in UJPR, each of the contributors was represent to analyze the 
most notable advances in his or her area and to also provide a critical interpretative review from 
his or her own unique perspective. Obviously, it would be better to leave that to the judgment of 
each contributor. Actually, UJPR is now recognized as an international and indexed journal in 
more than 40 locations and I think that our journal will achieve an impact factor and will be 
member of Scopus, ISI and NLM category number (Abstracts indexed in PubMed, NCBI/PMID) 
in nearest future. This is all our wishes. 
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